Harvard Bioscience (HBIO) Payables (2010 - 2026)

Harvard Bioscience (HBIO) has reported Payables for 17 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 31.81% year-over-year to $6.2 million in Q2 2026; TTM through Jun 2026 was $6.2 million, a 31.81% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, down 23.71% from the prior year.
• Payables was $6.2 million for Q2 2026 at Harvard Bioscience, up from $5.3 million in the prior quarter.
• Over five years, Payables peaked at $6.8 million in Q2 2022 and troughed at $3.7 million in Q4 2025.
• A 5-year average of $5.5 million and a median of $5.6 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables slumped 30.75% in 2023 and surged 31.81% in 2026, its largest moves.
• Over 5 years, Payables stood at $6.4 million in 2022, then retreated by 13.85% to $5.6 million in 2023, then fell by 13.81% to $4.8 million in 2024, then slipped by 23.71% to $3.7 million in 2025, then jumped by 70.43% to $6.2 million in 2026.
• The last three Payables figures came in at $6.2 million (Q2 2026), $5.3 million (Q1 2026), and $3.7 million (Q4 2025), per Business Quant data.